Literature DB >> 8394563

Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain.

J A Desmeules1, V Kayser, G Guilbaud.   

Abstract

This study evaluated the antinociceptive effects of systemically administered selective opioid agonists of mu (DAMGO), delta (BUBU) and kappa (U 69593) receptors on the vocalization threshold to paw pressure in a rat model of peripheral unilateral mononeuropathy produced by loose ligatures around the common sciatic nerve. DAMGO (0.5-2 mg/kg), BUBU (1.5-6 mg/kg) and U 69593 (0.75-3 mg/kg) injected intravenously (i.v.) produced a potent long-lasting antinociceptive effect on both hind paws. The effects on the lesioned paw were clearly and statistically more potent than for the non-lesioned paw. The selective antinociceptive effect of 2 mg/kg DAMGO, 3 mg/kg BUBU and 1.5 mg/kg U 69593 were completely prevented by prior administration of the appropriate antagonists: 0.1 mg/kg naloxone, 1 mg/kg naltrindole and 0.4 mg/kg MR 2266. The present data clearly show that an acute i.v. injection of these selective opioid agonists induces potent antinociceptive effects in a rat model of peripheral neuropathy. These data are discussed with regard to the classical view that there is opioid resistance in neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394563     DOI: 10.1016/0304-3959(93)90224-D

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

1.  Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.

Authors:  C Courteix; M A Coudoré-Civiale; A M Privat; J M Zajac; A Eschalier; J Fialip
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.

Authors:  Vanessa Minervini; Sujata Dahal; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-11-30       Impact factor: 4.030

3.  Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.

Authors:  Qing Shen; Yuanyuan Qian; Xiaoqin Huang; Xuejun Xu; Wei Li; Jinggen Liu; Wei Fu
Journal:  ACS Med Chem Lett       Date:  2016-02-10       Impact factor: 4.345

4.  Mu-opioid receptor in the nucleus submedius: involvement in opioid-induced inhibition of mirror-image allodynia in a rat model of neuropathic pain.

Authors:  Jun-Yang Wang; Mei Zhao; Fen-Sheng Huang; Jing-Shi Tang; Yu-Kang Yuan
Journal:  Neurochem Res       Date:  2008-05-13       Impact factor: 3.996

Review 5.  Delta Opioid Receptor Expression and Function in Primary Afferent Somatosensory Neurons.

Authors:  Amaury François; Grégory Scherrer
Journal:  Handb Exp Pharmacol       Date:  2018

6.  Passiflora incarnata attenuation of neuropathic allodynia and vulvodynia apropos GABA-ergic and opioidergic antinociceptive and behavioural mechanisms.

Authors:  Urooj Aman; Fazal Subhan; Muhammad Shahid; Shehla Akbar; Nisar Ahmad; Gowhar Ali; Khwaja Fawad; Robert D E Sewell
Journal:  BMC Complement Altern Med       Date:  2016-02-24       Impact factor: 3.659

Review 7.  G-Protein Coupled Receptors Targeted by Analgesic Venom Peptides.

Authors:  James T Daniel; Richard J Clark
Journal:  Toxins (Basel)       Date:  2017-11-16       Impact factor: 4.546

8.  Lithium reverses mechanical allodynia through a mu opioid-dependent mechanism.

Authors:  Ivan Weinsanto; Jinane Mouheiche; Alexis Laux-Biehlmann; Maya Aouad; Tando Maduna; Nathalie Petit-Demoulière; Virginie Chavant; Pierrick Poisbeau; Pascal Darbon; Alexandre Charlet; Anne Giersch; Marie-Odile Parat; Yannick Goumon
Journal:  Mol Pain       Date:  2018-01-21       Impact factor: 3.395

9.  Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors.

Authors:  John K Neubert; Heather L Rossi; Jonathan Pogar; Alan C Jenkins; Robert M Caudle
Journal:  Behav Brain Funct       Date:  2007-09-20       Impact factor: 3.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.